Anti-PACAP antibodies, nucleic acids and methods of making thereof
The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the V H , V L , and CDR polypeptides described herein, and the polynucleotides encoding them. Antibodies and antigen binding fragments described herein bind to and/or compete for binding to the same linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody. The invention contemplates conjugates of anti-PACAP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-PACAP antibodies and antigen binding fragments thereof are also contemplated. Other embodiments of the invention contemplate using anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, photophobia, mast cell degranulation, and/or neuronal activation, would be therapeutically beneficial.
1 . An isolated nucleic acid or nucleic acids encoding an anti-PACAP antibody or antigen-binding antibody fragment thereof, comprising: (i) a heavy chain variable region (VH) comprising a complementarity-determining region 1 (CDR1) sequence consisting of the amino acid sequence of SEQ ID NO: 1164, a complementarity-determining region 2 (CDR2) sequence consisting of the amino acid sequence of SEQ ID NO: 1166, and a complementarity-determining region 3 (CDR3) sequence consisting of the amino acid sequence of SEQ ID NO: 1168; and (ii) a light chain variable region (VL) comprising a CDR1 sequence consisting of the amino acid sequence of SEQ ID NO: 1184, a CDR2 sequence consisting of the amino acid sequence of SEQ ID NO: 1186, and a CDR3 sequence consisting of the amino acid sequence of SEQ ID NO: 1188, wherein: the encoded VH of (i) comprises an amino acid sequence with at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 1162, and the encoded VL of (ii) comprises an amino acid sequence with at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 1182, or a vector or vectors containing the isolated nucleic acid or nucleic acids.
2 . The isolated nucleic acid or nucleic acids encoding an anti-PACAP antibody or antigen-binding antibody fragment thereof according to claim 1 , wherein: (i) the encoded VH comprises an amino acid sequence with at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 1162 and comprises a CDR1 sequence consisting of the amino acid sequence of SEQ ID NO: 1164, a CDR2 sequence consisting of SEQ ID NO: 1166, and a CDR3 sequence consisting of the amino acid sequence of SEQ ID NO: 1168; and (ii) the encoded VL comprises an amino acid sequence with at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 1182 and comprises a CDR1 sequence consisting of the amino acid sequence of SEQ ID NO: 1184, a CDR2 sequence consisting of the amino acid sequence of SEQ ID NO: 1186, and a CDR3 sequence consisting of the amino acid sequence of SEQ ID NO: 1188.
3 . The isolated nucleic acid or nucleic acids encoding an anti-PACAP antibody or antigen-binding antibody fragment thereof according to claim 1 , wherein: (i) the encoded VH comprises an amino acid sequence with at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1162 and comprises a CDR1 sequence consisting of the amino acid sequence of SEQ ID NO: 1164, a CDR2 sequence consisting of SEQ ID NO: 1166, and a CDR3 sequence consisting of the amino acid sequence of SEQ ID NO: 1168; and (ii) the encoded VL comprises an amino acid sequence with at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1182 and comprises a CDR1 sequence consisting of the amino acid sequence of SEQ ID NO: 1184, a CDR2 sequence consisting of the amino acid sequence of SEQ ID NO: 1186, and a CDR3 sequence consisting of the amino acid sequence of SEQ ID NO: 1188.
4 . The isolated nucleic acid or nucleic acids encoding an anti-PACAP antibody or antigen-binding antibody fragment thereof according to claim 1 , wherein: (i) the encoded VH comprises an amino acid sequence with at least 99% sequence identity to the amino acid sequence of SEQ ID NO: 1162 and comprises a CDR1 sequence consisting of the amino acid sequence of SEQ ID NO: 1164, a CDR2 sequence consisting of SEQ ID NO: 1166, and a CDR3 sequence consisting of the amino acid sequence of SEQ ID NO: 1168; and (ii) the encoded VL comprises an amino acid sequence with at least 99% sequence identity to the amino acid sequence of SEQ ID NO: 1182 and comprises a CDR1 sequence consisting of the amino acid sequence of SEQ ID NO: 1184, a CDR2 sequence consisting of the amino acid sequence of SEQ ID NO: 1186, and a CDR3 sequence consisting of the amino acid sequence of SEQ ID NO: 1188.
5 . The isolated nucleic acid or nucleic acids encoding an anti-PACAP antibody or antigen-binding antibody fragment thereof according to claim 1 , wherein: (i) the encoded VH comprises the amino acid sequence of SEQ ID NO: 1162; and (ii) the encoded VL comprises the amino acid sequence of SEQ ID NO: 1182.
6 . The isolated nucleic acid or nucleic acids encoding an anti-PACAP antibody or antigen-binding antibody fragment thereof according to claim 1 , wherein the encoded anti-PACAP antibody comprises a heavy chain comprising a VH and a light chain comprising a VL, and wherein (i) the encoded heavy chain comprises an amino acid sequence with at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1161; and (ii) the encoded light chain comprises an amino acid sequence with at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1181, and wherein: the VH comprises a CDR1 sequence consisting of the amino acid sequence of SEQ ID NO: 1164, a CDR2 sequence consisting of SEQ ID NO: 1166, and a CDR3 sequence consisting of the amino acid sequence of SEQ ID NO: 1168; and the VL comprises a CDR1 sequence consisting of the amino acid sequence of SEQ ID NO: 1184, a CDR2 sequence consisting of the amino acid sequence of SEQ ID NO: 1186, and a CDR3 sequence consisting of the amino acid sequence of SEQ ID NO: 1188.
7 . The isolated nucleic acid or nucleic acids encoding an anti-PACAP antibody or antigen-binding antibody fragment thereof according to claim 6 , wherein:
(i) the encoded heavy chain comprises the amino acid sequence of SEQ ID NO: 1161; and
(ii) the encoded light chain comprises the amino acid sequence of SEQ ID NO: 1181.
8 . The isolated nucleic acid or nucleic acids encoding an anti-PACAP antibody or antigen-binding antibody fragment thereof according to claim 1 , wherein the encoded antibody comprises a human IgG constant domain, optionally wherein the human IgG is IgG1, IgG2, IgG3, or IgG4.
9 . The isolated nucleic acid or nucleic acids encoding an anti-PACAP antibody antigen-binding antibody fragment thereof according to claim 1 , wherein the encoded antibody comprises a Fc region comprising the amino acid sequence of SEQ ID NO: 1244, 1245, or 1246.
10 . The isolated nucleic acid or nucleic acids encoding an anti-PACAP antibody antigen-binding antibody fragment thereof according to claim 1 , wherein the encoded antibody comprises an Fc region which
(i) lacks N-glycosylation;
(ii) lacks O-glycosylation; or
(iii) lacks N-glycosylation and O-glycosylation.
11 . The isolated nucleic acid or nucleic acids encoding an anti-PACAP antibody or antigen binding fragment antibody or antigen-binding antibody fragment thereof according to claim 1 , wherein the encoded antigen-binding antibody fragment is selected from the group consisting of scFvs, fragment antigen-binding (Fab) fragments, Fab′ fragments, monovalent antigen-binding antibody fragments, and F(ab′) 2 fragments, wherein the antigen-binding antibody fragments comprise a heavy chain variable region (VH) and a light chain variable region (VL) comprising complementarity-determining regions according to claim 1 .
12 . An isolated nucleic acid or nucleic acids encoding an anti-PACAP antibody or antigen-binding antibody fragment thereof, wherein the anti-PACAP antibody comprises a heavy chain comprising a heavy chain variable region (VH) and a light chain comprising a light chain variable region (VL), and wherein the VH comprises a CDR1 sequence consisting of the amino acid sequence of SEQ ID NO: 1164, a CDR2 sequence consisting of SEQ ID NO: 1166, and a CDR3 sequence consisting of the amino acid sequence of SEQ ID NO: 1168; and the VL comprises a CDR1 sequence consisting of the amino acid sequence of SEQ ID NO: 1184, a CDR2 sequence consisting of the amino acid sequence of SEQ ID NO: 1186, and a CDR3 sequence consisting of the amino acid sequence of SEQ ID NO: 1188.
13 . The isolated nucleic acid or nucleic acids encoding an anti-PACAP antibody or antigen binding fragment thereof according to claim 12 , wherein the VH comprises the amino acid sequence of SEQ ID NO: 1162, and the VL comprises the amino acid sequence of SEQ ID NO: 1182.
14 . The isolated nucleic acid or nucleic acids encoding an anti-PACAP antibody or antigen binding fragment thereof according to claim 12 , wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 1161; and the light chain comprises the amino acid sequence of SEQ ID NO: 1181.
15 . The isolated nucleic acid or nucleic acids encoding an anti-PACAP antibody or antigen binding fragment thereof according to claim 12 wherein the antigen-binding antibody fragment is selected from the group consisting of scFvs, Fab fragments, Fab′ fragments, monovalent antigen-binding antibody fragments, and F(ab′) 2 fragments, wherein the antigen-binding antibody fragments comprise a heavy chain variable region (VH) and a light chain variable region (VL) comprising the complementarity determining regions according to claim 12 .
16 . An isolated recombinant host cell comprising the isolated nucleic acid or nucleic acids according to claim 1 or a vector or vectors comprising the isolated nucleic acid or nucleic acids.
17 . The isolated recombinant host cell of claim 16 , wherein the isolated recombinant host cell is a mammalian, bacterial, fungal, yeast, avian, amphibian, plant, CHO, or insect cell.
18 . The isolated recombinant host cell of claim 16 , wherein the isolated recombinant host cell is a filamentous fungus or a yeast selected from the group consisting of genera: Arxiozyma; Ascobotryozyma; Citeromyces; Debaryomyces; Dekkera; Eremothecium; Issatchenkia; Kazachstania; Kluyveromyces; Kodamaea; Lodderomyces; Pachysolen; Pichia; Saccharomyces; Saturnispora; Tetrapisispora; Torulaspora; Williopsis ; and Zygosaccharomyces.
19 . The isolated recombinant host cell of claim 16 , wherein the isolated recombinant host cell is selected from Pichia pastoris , and Pichia methanolica or Hansenula polymorpha ( Pichia angusta ).
20 . A method of expressing an anti-PACAP antibody or antigen binding fragment thereof comprising culturing the isolated, recombinant host cell of claim 16 , under conditions that provide for expression of the anti-PACAP antibody or antigen binding fragment thereof.
21 . The method of claim 20 , wherein the isolated, recombinant host cell is a yeast culture or CHO cell that stably expresses the anti-PACAP antibody or antigen binding fragment thereof.
22 . The method of claim 21 , wherein the yeast culture comprises a Pichia cell culture.